CENTESSA PHARMACEUTICALS PLC (CNTA)
Institutional ownership reported to the SEC as of Q2 2026, across 21 quarters.
1
Reporting holders
$231
Reported value
100.0%
Held as options
-158
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| SIMPLEX TRADING, LLC | $231 | options only | 0.00% | 2q | OPTIONS |
Five percent filings
Anyone crossing 5% of a company must say so within days - far sooner than the next quarterly holdings report. A 13D declares an intent to influence the company; a 13G is the passive version. See all activist filings →
| Filed | Form | Filer | % of class |
|---|---|---|---|
| 2026-08-14 | 13G/A | Pentwater Capital Management LPwith 1 co-filers | 0.0% |
| 2026-08-14 | 13G/A | INDEX VENTURES LIFE VI (JERSEY) L.P.with 2 co-filers | 0.0% |
| 2026-08-12 | 13G/A | Adage Capital Management, L.P.with 2 co-filers | 0.0% |
| 2026-08-04 | 13G/A | Medicxi Growth I LPwith 9 co-filers | 0.0% |
| 2026-07-08 | 13G/A | FMR LLCwith 1 co-filers | 0.0% |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | $231 | 0 | 0 | 0 | 0 | 100.0% |
| Q1 2026 | 159 | $5.9B | 147,998,975 | 50 | 48 | 44 | 0.9% |
| Q4 2025 | 140 | $3.5B | 139,512,541 | 37 | 44 | 44 | 0.5% |
| Q3 2025 | 124 | $3.1B | 124,284,823 | 24 | 33 | 50 | 1.7% |
| Q2 2025 | 116 | $1.6B | 117,424,114 | 19 | 42 | 37 | 0.7% |
| Q1 2025 | 127 | $1.7B | 117,314,258 | 34 | 40 | 35 | 0.8% |
| Q4 2024 | 107 | $1.9B | 115,042,762 | 15 | 31 | 35 | 0.2% |
| Q3 2024 | 98 | $1.6B | 100,248,794 | 30 | 41 | 16 | 0.1% |
| Q2 2024 | 74 | $744.6M | 82,445,258 | 15 | 25 | 17 | 0.0% |
| Q1 2024 | 63 | $848.9M | 75,097,724 | 17 | 25 | 6 | 0.0% |
| Q4 2023 | 54 | $545.2M | 68,469,975 | 10 | 15 | 9 | 0.0% |
| Q3 2023 | 46 | $452.9M | 69,976,191 | 6 | 13 | 10 | 0.0% |
| Q2 2023 | 40 | $412.9M | 66,691,685 | 5 | 12 | 7 | 0.0% |
| Q1 2023 | 37 | $246.3M | 63,975,523 | 4 | 12 | 7 | 0.0% |
| Q4 2022 | 36 | $223.9M | 60,944,455 | 2 | 10 | 5 | 0.0% |
| Q3 2022 | 42 | $300.4M | 74,754,089 | 5 | 7 | 13 | 0.0% |
| Q2 2022 | 40 | $350.3M | 71,831,750 | 7 | 12 | 9 | 0.0% |
| Q1 2022 | 43 | $669.1M | 74,581,598 | 4 | 15 | 13 | 0.0% |
| Q4 2021 | 47 | $807.8M | 71,874,085 | 12 | 18 | 7 | 0.0% |
| Q3 2021 | 39 | $947.5M | 56,915,301 | 5 | 12 | 12 | 0.0% |
| Q2 2021 | 49 | $1.0B | 47,409,920 | 49 | 0 | 0 | 0.0% |